CD33 and acute myeloid leukemia: Due to promising preclinical data, several CD33/CD3 BiTE antibodies, such as AMG 330, GEM333, AMG 673 (a half-life extended antibody), and AMV564 (in combination with pembrolizumab), are being investigated in phase I clinical trials in AML patients (NCT02520427, NCT03516760, NCT03224819, and NCT03144245).